Menu Search
Equities

hVIVO PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CRO:FRA

hVIVO PLC

Actions
  • Price (EUR)0.096
  • Today's Change0.00 / 0.00%
  • Shares traded20.00k
  • 1 Year change-49.47%
  • Beta2.0906
Data delayed at least 15 minutes, as of Feb 13 2026 13:38 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

hVIVO plc is a United Kingdom-based specialist early-stage drug development contract research organization (CRO) and human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base. It specializes in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its quarantine facility. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. The Company, through its subsidiary, operates an approximately 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. It also offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Company also provides industry-standard, temperature-controlled storage solutions for biological and clinical materials.

  • Revenue in GBP (TTM)51.28m
  • Net income in GBP5.28m
  • Incorporated2011
  • Employees301.00
  • Location
    hVIVO PLC40 Bank Street, Floor 24LONDON E14 5NRUnited KingdomGBR
  • Phone+44 207 756 1300
  • Websitehttps://hvivo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.